EARLY BIRD REGISTRATION ENDS SEPTEMBER 1!
![shutterstock_2658171737 [Converted]_Smaller.jpg](https://static.wixstatic.com/media/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg/v1/fill/w_980,h_327,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg)
Member Spotlight
Scott Clingan, PA-C, MSHS
Scott Clingan, PA-C, MSHS, has more than two decades of experience in pain medicine, with expertise spanning pharmacologic and interventional pain management, clinical leadership, and practice administration. Throughout his career, he has been actively involved in pain medicine education, serving as faculty and speaker at regional and national conferences on pain management, patient safety, opioid stewardship, and clinical education. Scott also remains engaged in professional organizations, including service with the Pain Society of the Carolinas, and previously presented at PMAAPP’s inaugural conference in 2025.
INDUSTRY NEWS
Will recent FDA approval of a novel
nonopioid analgesic be a game changer?
Physician's Weekly
The Food and Drug Administration recently approved Journavx, a first-in-class oral, nonopioid, highly selective sodium channel blocker indicated as a treatment for adults with moderate to severe acute pain. Clinical data revealed that this agent is an effective, well-tolerated medicine without evidence of addictive potential, indicated for use with all types of moderate to sever acute pain.
